Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBSM Prior Auth & Step Therapy Coverage | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    Medicare Plus Blue Group PPO / Prescription Blue Group PDP — Prior Authorization and Step Therapy Criteria (Pharmacy & Specialty Drugs)

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists prior authorization and step therapy requirements for multiple prescription drugs covered under the BCBSM Medicare Plus Blue Group PPO and Prescription Blue Group PDP Healthy Value Comprehensive Formulary for the 2026 plan year; intended for providers and pharmacists submitting PA/ST requests for affected members.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyPrior Authorization / Step Therapy Criteria for Medicare Plus Blue Group — Pharmacy & Specialty Drugs
    Policy CodePolicy N/A
    Change TypeMinor / no material change
    Effective Date
    Next Review Date
    Key ActionSubmit required prior-authorization documentation (diagnostic tests, prior therapy trials, or lab values) per the product-specific criteria when requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    390document length (pages)
    ~20+products listed (excerpt)
    1 YEARtypical auth duration
    manyprerequisite therapy present
    YEScombination biologic exclusion

    Product-level Coverage Criteria

    Adbry coverage

    Covered when ALL of the following are met:

    Adbry initial coverage: Indication is a medically-accepted indication; age >= 12 years; for atopic dermatitis requires diagnosis of moderate to severe atopic dermatitis and trial and treatment failure of one of: high potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil

    Coverage duration: 1 year; prerequisite Part D drug required; reauthorization requires documentation of positive clinical response; for patients <100 kg who achieve response after 16 weeks, dosage limited to 300 mg every 4 weeks unless clinical rationale provided

    Bronchitol coverage

    Covered when ALL of the following are met:

    Bronchitol initial coverage: Member has passed the Bronchitol tolerance test

    Coverage duration: 1 year

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyPrior Authorization / Step Therapy Criteria for Medicare Plus Blue Group — Pharmacy & Specialty Drugs
    Policy CodePolicy N/A
    Change TypeMinor / no material change
    Effective Date
    Next Review Date
    Key ActionSubmit required prior-authorization documentation (diagnostic tests, prior therapy trials, or lab values) per the product-specific criteria when requesting coverage.
    SourceLink
    On This Page
    Product-level Coverage CriteriaCodes, Clinical Thresholds and Key ValuesPrior Authorization, Step Therapy and Documentation RequirementsRequirements to Start TherapyReauthorization and Ongoing UseStep Therapy Tables and Prior TrialsPlace of Service ConsiderationsPolicy Background and ScopeKey Definitions

    Tadalafil coverage/exclusion

    Tadalafil (BPH indication):

    Tadalafil coverage for BPH: Diagnosis of benign prostatic hyperplasia

    Coverage not provided when patient is receiving nitrate therapy; coverage duration: 1 year

    Anticonvulsant prerequisite therapy

    Certain anticonvulsant agents:

    Anticonvulsant prerequisite therapy: Coverage requires trial of divalproex or valproic acid and lamotrigine (examples include brivaracetam/Briviact and other anticonvulsant products that list this requirement)

    Coverage duration: 1 year; document trials

    Levetiracetam oral-solution prerequisite (example): For formulations where oral solution is required (e.g., levetiracetam IV alternative), coverage requires trial of levetiracetam oral solution and that the patient is unable to swallow tablets/capsules

    Document inability to swallow; coverage duration: 1 year

    Biologics / targeted DMARDs - general rules

    Covered when ALL of the following are met (general biologic/targeted DMARD rules):

    Biologic/targeted DMARD general rules: Indication is a medically-accepted indication for the product; product is not used in combination with another biologic or targeted DMARD indicated for the same condition; where specified, prior trials or other indication-specific requirements are met

    Coverage duration commonly 1 year; many products require prerequisite Part D drug trials and reauthorization requires documentation of positive clinical response

    Dupixent - indication-specific criteria

    Dupixent — indication-specific rules (examples):

    Atopic dermatitis (AD): Diagnosis of moderate to severe atopic dermatitis; age per product labeling (AD: as specified) and trial and treatment failure of one of: high-potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetilage thresholds vary by indication (e.g., AD: >=6 months)

    Reauthorization requires documentation of positive clinical response; cannot be used in combination with another biologic/targeted DMARD for same condition

    Eosinophilic asthma (EA): Diagnosis of eosinophilic asthma with eosinophil count >=150 cells/µL at initiation and failure to maintain adequate control after systemic corticosteroids or high-dose inhaled corticosteroids plus trial of an additional controller (e.g., leukotriene modifier, LABA, or LAMA)>=150 cells/µL

    Reauthorization requires documentation of response; cannot be used in combination with another biologic/targeted DMARD for same condition

    Dalfampridine - initiation and reauthorization

    Dalfampridine — initiation and reauthorization:

    Dalfampridine initiation: Submission of baseline timed 25-foot walk (T25FW) test prior to initiation; patient is not wheelchair bound and does not become wheelchair bound

    Reauthorization requires documentation of stability or improvement on T25FW; coverage duration: 1 year

    Prerequisite therapy required examples

    Products requiring prerequisite DMARD or prior therapies (examples):

    Schizophrenia prerequisite examples: Coverage for schizophrenia-related products requires trial of at least two second-generation antipsychotics or other specified conventional agents as listed per product

    Document trials and durations as applicable; some products have lifetime coverage durations

    Rheumatoid arthritis prerequisite (example: Enbrel-class rules): Diagnosis of moderately to severely active rheumatoid arthritis and trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine) prior to coverage of targeted agents

    Reauthorization generally requires documentation of positive clinical response

    Preventative migraine coverage

    Coverage for preventive treatment of migraine is provided when one of the following is met:

    Migraine preventive coverage: 1) Trial of at least 2 generic alternatives for migraine prevention, OR 2) patient is unable to swallow tablets/capsules

    Coverage duration: 1 year; document trials or inability to swallow

    Seizure disorder/epilepsy coverage

    Coverage for treatment of seizure disorder/epilepsy requires:

    Seizure disorder/epilepsy prerequisites: 1) Trial of at least 2 generic anticonvulsants (one example requirement for some products is levetiracetam plus another agent), OR 2) patient is unable to swallow tablets/capsules

    Document trials and baseline assessments as required; coverage duration commonly 1 year

    Schizophrenia coverage

    Coverage for treatment of schizophrenia requires ALL of the following:

    Schizophrenia coverage criteria: Trial of two generic formulary atypical antipsychotics (examples include aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) or, where specified, trial of a conventional antipsychotic per product requirements

    Document trials; coverage duration for listed products may be lifetime

    Fasenra - Eosinophilic asthma (EA) coverage

    Fasenra — Eosinophilic asthma (EA) coverage (initiation):

    Fasenra EA initiation: Diagnosis of eosinophilic asthma with eosinophil count >=150 cells/µL at initiation; failure to maintain adequate control after trial of systemic corticosteroids or high-dose inhaled corticosteroids plus trial of one additional asthma controller medication (leukotriene modifier, LABA, or LAMA)>=150 cells/µL

    Reauthorization requires documentation of positive clinical response; cannot be used in combination with another biologic/targeted DMARD for same condition

    Fasenra - EGPA coverage

    Fasenra — EGPA coverage:

    Fasenra EGPA criteria: Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) and history or presence of asthma plus at least two typical EGPA clinical features (examples: histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, allergic rhinitis/nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity)

    Reauthorization requires documentation of positive clinical response; cannot be used in combination with another biologic/targeted DMARD for same condition

    Tumor necrosis factor / Adalimumab-class coverage (examples)

    Coverage for specified indications requires diagnosis plus prior therapy trials:

    RA example (TNF/adalimumab-class): Diagnosis of moderately to severely active rheumatoid arthritis and trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine) prior to coverage of biologic/adalimumab-class agents

    Reauthorization requires documentation of positive clinical response; cannot be used in combination with another biologic/targeted DMARD for same condition

    Ankylosing spondylitis example: Diagnosis of active ankylosing spondylitis and trial of one NSAID (e.g., diclofenac, ibuprofen, meloxicam, naproxen) prior to coverage

    Document trial

    Teriparatide (Forteo) coverage

    Teriparatide (Forteo) — covered when ALL of the following are met:

    Teriparatide criteria: Documentation of bone mineral density T-score <= -2.5 AND trial of Jubbonti or Stoboclo AND trial of either an oral bisphosphonate (or IV bisphosphonate if intolerant); coverage also provided if unable to be treated with those agentsT-score <= -2.5

    Coverage duration: 2 years; document trials

    GLP-1 agonists / incretin agents (examples: Mounjaro, Ozempic, Rybelsus, Trulicity)

    GLP-1 agonists / incretin agents — coverage requires diabetes documentation and excludes weight-loss-only use:

    T2DM documentation for GLP-1s: For ongoing treatment of type 2 diabetes mellitus, submit medical records confirming diagnosis of T2DM OR lab evidence (A1c >=6.5% OR fasting plasma glucose >=126 mg/dL OR 2-hour plasma glucose >=200 mg/dL during OGTT)A1c >=6.5% or FPG >=126 mg/dL or 2-hr PG >=200 mg/dL

    Excluded if used for weight loss only; coverage duration: 1 year

    Ibrance (palbociclib) coverage

    Ibrance (palbociclib) — coverage for HR+/HER2- advanced/metastatic breast cancer:

    Ibrance combination requirements: Combination with an aromatase inhibitor as initial endocrine-based therapy OR combination with fulvestrant for progression after endocrine therapy; other indication-specific combinations per product labeling

    Coverage duration: 1 year; document combination endocrine therapy

    Product-specific coverage criteria

    Product-specific coverage criteria (selected examples):

    Selected autoimmune/inflammatory and oncology product criteria: Each product requires its listed indication-specific diagnostic criteria, prerequisite therapy trials, combination use, and documentation as specified in its entry (examples include requirements for UC/HS/uveitis, IVIG Part B vs D review, Kevzara/TOCILIZUMAB prerequisite trials, Joenja APDS genetic confirmation, and oncology combination/prior therapy rules)

    Many require prerequisite Part D drug trials; reauthorization generally requires documentation of positive clinical response

    Product-specific coverage criteria

    Representative product-specific coverage criteria (examples):

    Lynparza (selected oncology indications): Coverage for BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer requires prior trial of platinum-based chemotherapy; some ovarian indications require combination with bevacizumab; other indications require prior specified therapies

    Coverage duration: 1 year; document prior platinum-based chemotherapy

    Mekinist BRAF-mutant indications: Coverage for unresectable or metastatic melanoma with BRAF V600E or V600K mutations provided as monotherapy only for BRAF-inhibitor treatment–naive patients; otherwise combination use (e.g., with dabrafenib) or trial of specified BRAF/MEK regimens is required; solution formulation requires inability to swallow tablets

    Mutation must be detected by FDA-approved test; document prior regimens

    Liraglutide for T2DM: Documentation of T2DM diagnosis by records or lab evidence (A1c >=6.5% or FPG >=126 mg/dL or 2-hr PG >=200 mg/dL); excluded if used for weight loss onlyA1c >=6.5% or FPG >=126 mg/dL or 2-hr PG >=200 mg/dL

    Coverage duration: 1 year

    Nucala: Indication-specific coverage

    Nucala — indication-specific coverage:

    Nucala general and indication-specific criteria: Eosinophilic asthma: diagnosis with eosinophil count >=150 cells/µL at initiation AND failure to maintain control after systemic corticosteroids or high-dose inhaled corticosteroids plus trial of one additional controller (leukotriene modifier, LABA, or LAMA). EGPA: diagnosis with at least two typical EGPA features. HES: eosinophil count >=1000 cells/µL at initiation and stability on HES therapy. CRSwNP: recurrent disease despite intranasal corticosteroids. COPD add-on: uncontrolled moderate-to-severe COPD with eosinophil criteria and current LABA+LAMA+ICS unless contraindicated.see node text

    Reauthorization requires documentation of positive clinical response; cannot be used in combination with another biologic/targeted DMARD for same condition

    Mektovi: Combination therapy requirements

    Mektovi — combination therapy requirements (examples):

    Mektovi coverage: Coverage for unresectable or metastatic melanoma with BRAF V600E or V600K requires trial of vemurafenib + cobimetinib used in combination; certain melanoma and metastatic NSCLC indications require combination use with encorafenib

    Coverage duration: 1 year; document prior combination trial where applicable

    Nexletol/Nexlizet: Statin prerequisite

    Nexletol / Nexlizet — statin prerequisite:

    Statin prerequisite for Nexletol/Nexlizet: Diagnosis of hypercholesterolemia (including HeFH) or increased CV risk AND trial of one high-intensity statin unless documented intolerance or contraindication; LDL while on high-intensity statin within last 120 days must meet specified thresholdsLDL >=55 mg/dL with ASCVD; LDL >70 mg/dL without ASCVD (measured while on high-intensity statin within last 120 days)

    Document statin trial or intolerance; coverage duration: 1 year

    Opfolda: Diagnostic confirmation and clinical criteria

    Opfolda — diagnostic confirmation and clinical criteria:

    Opfolda diagnostic confirmation: Confirmation of diagnosis by serum assay showing decreased acid alpha-glucosidase activity AND genetic testing demonstrating a GAA mutation; presence of symptomatic manifestations (e.g., progressive muscle weakness, respiratory failure, frequent upper airway infections, orthopnea, sleep apnea, morning headaches) and no improvement on current enzyme replacement therapy

    Coverage duration: 1 year; prerequisite Part D drug required; document assay and genetic testing

    Opfolda — AML post-remission coverage

    Opfolda — AML post-remission coverage (example):

    Opfolda AML post-remission: Adult patient with acute myeloid leukemia who achieved first complete remission (CR) or CRi following intensive induction chemotherapy AND is not able to complete intensive curative therapy

    Coverage duration: 1 year; document CR/CRi status and inability to complete curative therapy

    Opfolda/related agent — Pompe disease

    Opfolda / related agent — Pompe disease:

    Opfolda (Pompe disease) diagnostic criteria: Serum assay showing decreased acid alpha-glucosidase activity AND genetic testing showing a mutation in the GAA gene; symptomatic manifestations must be present (not isolated cardiac hypertrophy) and no improvement on current enzyme replacement therapy

    Coverage duration: 1 year; prerequisite Part D drug required; document assay, genetic testing, and symptoms

    Orenitram and Jubbonti/Stoboclo — PAH and osteoporosis

    Orenitram and Jubbonti/Stoboclo — PAH and osteoporosis agents:

    Orenitram (PAH): Diagnosis of pulmonary arterial hypertension AND trial and failure or contraindication to sildenafil

    Coverage duration: 1 year; document prior PDE5 inhibitor trial

    Jubbonti / Stoboclo (osteoporosis): Trial of an oral bisphosphonate OR intolerance to oral bisphosphonate with trial of IV bisphosphonate OR unable to be treated with both oral and IV bisphosphonates

    Coverage excludes hypocalcemia; coverage duration: 3 years; document trials or intolerance

    Posaconazole DR — IFI prophylaxis and treatment criteria

    Posaconazole DR — prophylaxis and treatment criteria:

    Posaconazole prophylaxis: Patient at high risk of invasive fungal infection due to HSCT with GVHD or hematologic malignancy with prolonged neutropenia OR prior fungal infection requiring secondary prophylaxis; requires trial with two of fluconazole, itraconazole, or voriconazole

    Coverage duration: 6 months for prophylaxis; document prior azole trials

    Posaconazole treatment: Used as treatment of invasive fungal infections caused by Aspergillus and Candida; treatment coverage requires trial with two alternative agents (e.g., fluconazole, itraconazole, voriconazole)

    Document prior therapy trials

    Praluent — initial and reauthorization criteria

    Praluent — initial and reauthorization criteria:

    Praluent initial: Confirmation of ASCVD, primary hyperlipidemia, or HeFH per clinical criteria AND LDL while on a high-intensity statin within last 120 days meeting thresholds (ASCVD: LDL >=55 mg/dL; without ASCVD: LDL >70 mg/dL); trial of at least 12 weeks of high-intensity statin unless intolerantLDL >=55 mg/dL with ASCVD; LDL >70 mg/dL without ASCVD

    Document LDL while on high-intensity statin and statin trial/intolerance; coverage duration: 3 years for reauthorization

    Praluent reauthorization: Patient continues statin at max tolerated dose (unless documented inability) and has experienced LDL reduction while on Praluent; HoFH patients continue other lipid-lowering therapy and show LDL reduction

    Coverage duration: 3 years; document LDL response

    Piqray — PIK3CA-mutated breast cancer

    Piqray (alpelisib) — PIK3CA‑mutated breast cancer:

    Piqray coverage: Adult patients with HR-positive, HER2-negative, PIK3CA‑mutated advanced or metastatic breast cancer with progression on or after an endocrine-based regimen and use in combination with fulvestrant

    Coverage duration: 1 year; document PIK3CA mutation and prior endocrine therapy

    Pomalidomide — disease-specific criteria

    Pomalidomide — disease‑specific criteria (examples):

    Multiple myeloma: At least two prior therapies including lenalidomide and a proteasome inhibitor with disease progression on or within 60 days of last therapy; combination use with dexamethasone

    Coverage duration: 1 year; document prior therapies

    AIDS-related Kaposi sarcoma: Trial and failure of highly active antiretroviral therapy (HAART)

    Document HAART trial

    Eltrombopag — platelet count–based criteria

    Eltrombopag — platelet count–based criteria:

    Immune thrombocytopenia (ITP): Baseline platelet count <30,000/mcL AND trial of corticosteroids, immunoglobulins, or splenectomy<30,000/mcL

    Coverage duration: 1 year; document baseline platelet count and prior therapies

    Thrombocytopenia with chronic hepatitis C: Baseline platelet count <75,000/mcL<75,000/mcL

    Document baseline platelet count

    Severe aplastic anemia: Baseline platelet count <30,000/mcL<30,000/mcL

    Document baseline platelet count

    Jubbonti / Stoboclo bisphosphonate prerequisite

    Jubbonti / Stoboclo — bisphosphonate prerequisite:

    Bisphosphonate prerequisite: Trial of an oral bisphosphonate OR, if intolerant, an IV bisphosphonate; coverage also provided if patient unable to be treated with both oral and IV bisphosphonates

    Coverage duration: 3 years for listed products; coverage excludes hypocalcemia

    Eltrombopag Olamine clinical criteria

    Eltrombopag Olamine — clinical criteria (summary):

    Eltrombopag Olamine criteria: For ITP: baseline platelet count <30,000/mcL AND trial of corticosteroids, immunoglobulins, or splenectomy; for thrombocytopenia with chronic hepatitis C: baseline platelet count <75,000/mcL; for severe aplastic anemia: baseline platelet count <30,000/mcLsee node text

    Coverage duration: 1 year; document baseline labs and prior therapies

    Retevmo indication criteria

    Retevmo — indication criteria:

    Retevmo coverage: Adult patients with locally advanced or metastatic NSCLC with RET gene fusion OR adult and pediatric patients >=2 years with medullary thyroid cancer with RET mutation OR patients >=2 years with advanced/metastatic thyroid cancer with RET fusion; RET status must be detected by an FDA‑approved test; some thyroid indications require prior radioactive iodine if appropriate

    Coverage duration: 1 year; document RET gene fusion/mutation testing results

    NASH/MASH coverage and renewal criteria

    NASH / MASH — coverage and renewal criteria:

    NASH/MASH initial and renewal criteria: Diagnosis of noncirrhotic NASH or MASH with advanced liver fibrosis (stage F2 to F3) verified by FibroScan or other imaging-based non-invasive assessment AND trial of semaglutide prior to coverage; renewal requires no progression to cirrhosis AND one of: NASH/MASH resolution without worsening fibrosis; improvement in fibrosis >=1 stage without worsening NASH/MASH; or improvement/stabilization demonstrated by imaging or blood-based non-invasive assessmentF2-F3 fibrosis stage

    Coverage duration: 1 year; document semaglutide trial and fibrosis verification

    Rinvoq indication-specific criteria

    Rinvoq (upadacitinib) — indication‑specific criteria (summary):

    Rinvoq indication-specific criteria: Coverage for listed autoimmune/inflammatory indications requires diagnosis and prior therapy trials appropriate to that indication (e.g., trial of a DMARD for RA; trial of an NSAID for AS/axSpA; inadequate response/intolerance to one or more TNF inhibitors where specified); reauthorization requires documentation of positive clinical response and avoidance of combination with a potent immunosuppressant or another biologic/targeted DMARD for the same condition

    Coverage duration: 1 year; document prior trials and response

    Rivfloza coverage criteria

    Rivfloza — coverage criteria (PH1):

    Rivfloza (lumasiran) for PH1: Diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by genetic testing of the AGXT mutation

    Coverage duration: 1 year; exclusions include history of kidney or liver transplant and combination use with OXLUMO; document AGXT genetic testing

    Secuado formulation-based coverage

    Secuado — formulation‑based coverage (schizophrenia):

    Secuado coverage: Coverage for treatment of schizophrenia requires a trial of asenapine sublingual tablet OR documentation of difficulty using oral or orally disintegrating tablet (ODT) formulations

    Coverage duration: lifetime; document trial or documented difficulty swallowing; prerequisite Part D drug required

    Selected product criteria

    Selected product criteria (examples):

    Scemblix / multiple myeloma example: Coverage for multiple myeloma requires treatment with at least 2 prior therapies including lenalidomide and a proteasome inhibitor; relapsed/refractory disease requires 1–3 prior lines; newly diagnosed not eligible for ASCT requires combination with bortezomib, lenalidomide and dexamethasone

    Coverage duration: 1 year; prerequisite Part D drug required; document prior therapies

    Tafinlar (capsule & liquid): Coverage for BRAF V600E/V600K mutant unresectable or metastatic melanoma requires trial of vemurafenib + cobimetinib used in combination; liquid formulation requires inability to swallow capsules; many indications require combination with trametinib or other partner agents

    Coverage duration: 1 year; document prior combination therapies and inability to swallow if requesting liquid formulation

    Secuado

    Secuado / Sirturo / Spritam / Sunosi — single-node examples:

    Secuado (schizophrenia): Trial of asenapine sublingual tablet OR documentation of difficulty with oral/ODT formulations

    Coverage duration: lifetime; prerequisite Part D drug required

    Sirturo (bedaquiline): Bedaquiline must be used as part of a combination regimen for coverage

    Coverage duration: 1 year

    Spritam: Coverage requires trial of 2 generic anticonvulsants

    Coverage duration: 1 year; document trials

    Sunosi: Coverage requires trial of armodafinil

    Coverage duration: 1 year; document trial

    Sirturo

    Sirturo — coverage condition:

    Sirturo (bedaquiline) requirement: Bedaquiline must be used as part of a combination regimen for coverage

    Coverage duration: 1 year; document combination regimen

    Spritam

    Spritam / Tafinlar (examples):

    Spritam requirement: Coverage requires trial of 2 generic anticonvulsants

    Coverage duration: 1 year; document trials

    Tafinlar (capsule & liquid): Coverage for BRAF V600E/V600K mutant indications requires specified combination trials (e.g., vemurafenib + cobimetinib) and liquid formulation requires inability to swallow capsules

    Coverage duration: 1 year; document prior therapies and inability to swallow for liquid

    Sunosi

    Sunosi — example criterion:

    Sunosi prerequisite: Coverage requires trial of armodafinil

    Coverage duration: 1 year; document trial

    Tafinlar

    Tafinlar — formulation and indication notes:

    Tafinlar (capsule): Coverage for unresectable or metastatic melanoma with BRAF V600E or V600K requires trial of vemurafenib + cobimetinib used in combination; many solid-tumor indications require combination with trametinib

    Coverage duration: 1 year; document prior combination therapy

    Tafinlar (liquid): Coverage requires that the patient is unable to swallow capsule formulation; same indication-specific prior therapy requirements apply

    Coverage duration: 1 year; document inability to swallow

    Tagrisso

    Tagrisso — indication snapshot:

    Tagrisso (osimertinib): Coverage for EGFR exon 19 deletion- or exon 21 L858R mutation-positive NSCLC as adjuvant after resection, as first-line metastatic treatment, or in combination with pemetrexed and platinum-based chemotherapy for locally advanced/metastatic disease; T790M-positive disease coverage requires progression on/after EGFR TKI therapy

    Mutation detection by FDA‑approved test; coverage duration: 1 year

    Nilotinib

    Nilotinib — coverage condition (example):

    Nilotinib coverage: Coverage for adult patients with chronic phase CML not newly diagnosed and accelerated phase Ph+ CML requires a trial of prior therapy that included imatinib; pediatric coverage requires prior TKI therapy

    Coverage duration: 1 year; document prior TKI therapy

    General coverage statement

    General coverage statement (applies across many listed products):

    General product coverage: Many listed products are covered for their medically‑accepted indications with specified coverage durations (commonly 1 year) unless additional indication‑specific criteria are listed; where specified, prerequisite Part D drug trials, diagnostic testing, or combination therapy requirements must be met

    See individual product entries for specific prerequisites or restrictions; reauthorization generally requires documentation of positive clinical response

    TOCILIZUMAB: Indication-specific criteria

    Tocilizumab — indication‑specific criteria (summary):

    Tocilizumab (tocilizumab) coverage: Coverage for rheumatoid arthritis requires diagnosis of moderately to severely active RA and trial of two among: Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia; polyarticular JIA and other indications have analogous trial requirements; reauthorization requires documentation of positive clinical response

    Cannot be used in combination with another biologic or targeted DMARD for the same condition; document prior trials

    Tetrabenazine: Exclusions and testing

    Tetrabenazine — exclusions and testing:

    Tetrabenazine exclusions and testing: Coverage will not be provided for patients with hepatic function impairment, active suicidal ideation or untreated/inadequately treated depression, or concurrent use of MAO inhibitors or reserpine; documentation of CYP2D6 genotype is required for doses above 50 mg/dayDose >50 mg/day requires CYP2D6 genotype

    Do not combine with contraindicated agents; document genotype when applicable

    Tymlos: Eligibility and prerequisites

    Tymlos — eligibility and prerequisites:

    Tymlos eligibility: Documentation of bone mineral density T-score <= -2.5 AND prior trial of Jubbonti or Stoboclo AND either an oral bisphosphonate (or IV bisphosphonate if intolerant); coverage also provided if unable to be treated with listed alternativesT-score <= -2.5

    Coverage duration: 2 years; document BMD and bisphosphonate trials/intolerance

    VERZENIO: Indication-specific criteria

    Verzenio — indication‑specific criteria (examples):

    Verzenio indications: Adjuvant HR+ HER2- node-positive early breast cancer at high risk requires combination with tamoxifen or an aromatase inhibitor; advanced/metastatic disease requires combination with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant after progression; some monotherapy uses require prior endocrine and chemotherapy

    Document combination endocrine therapy or prior regimens per indication; coverage duration: 1 year

    Voquezna: H. pylori treatment criteria

    Voquezna — H. pylori treatment criteria:

    Voquezna H. pylori coverage: Diagnosis of Helicobacter pylori infection AND trial of a guideline‑recommended generic first‑line regimen (clarithromycin triple therapy or bismuth quadruple therapy) prior to coverage

    Coverage duration: 1 year; document prior first-line regimen trial; prerequisite Part D drug required

    Voquezna — H. pylori treatment

    Voquezna (Dual/Triple Pak) — covered when ALL of the following are met:

    Voquezna (Dual/Triple Pak) coverage criteria: Diagnosis of H. pylori infection AND trial of a generic, guideline‑recommended, first‑line regimen (clarithromycin triple therapy or bismuth quadruple therapy)

    Coverage duration: 1 year; prerequisite Part D drug required; document diagnosis and prior regimen

    Vosevi — Hepatitis C

    Vosevi — Hepatitis C:

    Vosevi coverage: Coverage applied consistent with current AASLD/IDSA guidance for hepatitis C virus infection

    Document clinical indications per guidance; coverage duration per guidance

    Welireg — oncology indications & prerequisites

    Welireg — oncology indications & prerequisites (summary):

    Welireg indications: Coverage for pheochromocytoma/paraganglioma; advanced RCC with clear cell component requires prior PD‑1/PD‑L1 inhibitor and VEGF‑TKI; coverage for VHL disease provided for patients requiring therapy for associated RCC, CNS hemangioblastomas, or pancreatic neuroendocrine tumors

    Prerequisite Part D drug required; document prior therapies

    Winrevair — PAH

    Winrevair — PAH criteria (example):

    Winrevair PAH criteria: Diagnosis of pulmonary arterial hypertension AND prior trial of both: 1) generic sildenafil or tadalafil AND 2) generic bosentan or ambrisentan

    Coverage duration: 1 year; document prior PDE5 inhibitor and ERA trials

    Xdemvy — Demodex blepharitis

    Xdemvy — Demodex blepharitis:

    Xdemvy coverage: Diagnosis of Demodex blepharitis confirmed by presence of collarettes on slit lamp exam

    Coverage duration: 1 year; document slit lamp findings

    Xifaxan — indication-specific prerequisite therapy

    Xifaxan 550 mg — indication‑specific prerequisite therapy:

    Xifaxan indication-based requirements: Hepatic encephalopathy: trial of lactulose; IBS‑D: trial of at least one of loperamide, dicyclomine, or diphenoxylate/atropine; recurrent C. difficile: trial of vancomycin

    Coverage duration: typically 1 year; document prior trials

    Xolair — allergy and ENT indications

    Xolair — allergy and ENT indications (summary):

    Xolair allergic asthma: Diagnosis of uncontrolled moderate to severe allergic asthma with positive skin or in vitro reactivity to a perennial aeroallergen AND IgE within specified range AND failure to maintain adequate control after systemic corticosteroids or high‑dose inhaled corticosteroids plus trial of an additional controller (leukotriene modifier, LABA, or LAMA)IgE ranges per age group

    Reauthorization requires positive clinical response; cannot be used with another biologic/targeted DMARD for same condition; document IgE and allergen testing

    Xolair CSU: Diagnosis of chronic spontaneous urticaria with symptoms despite H1 antihistamine treatment AND trial of at least one second‑generation antihistamine

    Reauthorization requires positive clinical response

    Xolair CRSwNP: Diagnosis of chronic rhinosinusitis with nasal polyposis with recurrent CRSwNP despite intranasal corticosteroidsIgE 30–1500 IU/mL at initiation

    Reauthorization requires positive clinical response; document IgE and prior intranasal steroid therapy

    Voydeya — PNH EVH

    Voydeya — PNH extravascular hemolysis (EVH):

    Voydeya EVH criteria: Clinically significant extravascular hemolysis due to PNH with hemoglobin <=9.5 g/dL AND absolute reticulocyte count >=120 x10^9/L AND use in combination only with Soliris or UltomirisHgb <=9.5 g/dL; retic >=120 x10^9/L

    Coverage duration: 1 year; document labs and combination therapy with Soliris/Ultomiris

    Abiraterone products

    Abiraterone products — prerequisite trial:

    Abiraterone prerequisite: Coverage for specified prostate cancer indications requires trial of abiraterone 250 mg tablet strength prior to coverage of other abiraterone products

    Document trial of abiraterone 250 mg tablets

    Zilbrysq (myasthenia gravis)

    Zilbrysq — myasthenia gravis coverage:

    Zilbrysq MG criteria: Documentation of anti‑AChR antibody‑positive myasthenia gravis AND one confirmatory test (positive edrophonium, history of response to cholinesterase inhibitors, or electrophysiological evidence by RNS or SFEMG); prior treatment courses of at least 12 weeks with one of methotrexate, azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, or tacrolimus unless contraindicated or not tolerated; patient must be on and continue a stable regimen

    Exclusions: no thymectomy within 12 months, no current thymoma or other thymus neoplasms; cannot be combined with other biologic therapies for MG or immunoglobulin therapy; document antibody testing and prior therapies

    Sodium oxybate

    Sodium oxybate — coverage conditions and exclusions:

    Sodium oxybate coverage: Diagnosis of cataplexy or excessive daytime sleepiness with narcolepsy AND for patients ≥18 years a trial of armodafinil and Sunosi (solriamfetol) is required

    Coverage duration: 1 year; exclusions include patients taking sedative hypnotics or with succinic semialdehyde dehydrogenase deficiency

    Zurzuvae (postpartum depression)

    Zurzuvae — postpartum depression:

    Zurzuvae coverage: Diagnosis of postpartum depression with onset in third trimester or within 4 weeks postpartum AND member is currently ≤ 12 months postpartum

    Coverage duration: 60 days; document timing of onset and postpartum status

    Zejula

    Zejula — maintenance therapy criteria:

    Zejula maintenance: Complete or partial response to first‑line platinum‑based chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer is required for maintenance treatment; for BRCA‑mutated recurrent disease similar response requirement applies

    Coverage duration: 1 year; document chemo response

    Zepzelca

    Zepzelca — small cell lung cancer criteria:

    Zepzelca indications: Metastatic SCLC: disease progression on or after platinum‑based chemotherapy; maintenance extensive‑stage SCLC requires combination use with atezolizumab (with or without hyaluronidase‑TQIS and carboplatin/etoposide) and confirmation disease not progressed after first‑line induction therapy

    Coverage duration: 1 year; document prior platinum‑based chemotherapy and induction regimen response

    Zarxio (AML)

    Zarxio — AML coverage condition:

    Zarxio (AML): Coverage for acute myeloid leukemia requires prior induction or consolidation chemotherapy treatment

    Coverage duration: 1 year; document prior chemotherapy

    Caplyta / Rexulti / Vraylar CAPS / Zyprexa Relprevv criteria

    Antidepressant and antipsychotic step/coverage requirements (examples):

    Antidepressant-class step therapy: Requires trial of at least 2 of the listed generic antidepressants (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, phenelzine, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, venlafaxine, vilazodone)2 agents

    Coverage duration is lifetime; document trials

    Conventional antipsychotic trial: Requires trial of at least one listed conventional antipsychotic (examples: aripiprazole, asenapine, haloperidol, olanzapine injection, paliperidone, quetiapine, risperidone, ziprasidone)1 agent

    Coverage duration is lifetime; document trial or intolerance

    Products requiring conventional antipsychotic trial

    Products requiring conventional antipsychotic or specific aripiprazole trials (selected entries):

    Conventional antipsychotic trial (product group): Requires trial of at least one listed conventional antipsychotic agent prior to coverage of certain products1 agent

    Coverage duration often lifetime; document trial or intolerance

    Aristada / Aristada Initio requirements: Aristada: requires trial or intolerance to Abilify Maintena or oral aripiprazole; Aristada Initio: requires trial of oral aripiprazoletrial or intolerance documented

    Coverage duration: lifetime; document trial durations where specified

    Product-specific coverage criteria

    Supply and injectable product prerequisites (examples):

    Insulin-related supply requirement: Coverage for specified supply products requires a claim for an insulin product in the last 180 daysclaim within 180 days

    Coverage duration: 1 year; document insulin claim

    Invega Hafyera paliperidone trial: Requires trial of a once-a-month paliperidone palmitate ER injectable for at least 4 months OR every-3-month paliperidone palmitate ER for at least one 3‑month cyclemonthly x >=4 months OR three-month x >=1 cycle

    Coverage duration: lifetime; document trial duration

    Pancreaze prerequisite: Requires trial or intolerance to Zenpep prior to coverage of Pancreaze formulations

    Coverage duration: lifetime; document trial or intolerance

    Product-specific step therapy and trial requirements

    Product-specific step therapy and trial requirements (selected examples):

    Rasuvo: Requires trial of generic injectable methotrexate prior to coverage

    Coverage duration: lifetime; document methotrexate trial

    Risperidone ER / Rykindo etc.: Requires trial of oral risperidone prior to coverage

    Coverage duration: lifetime; document trial

    Rhopressa / Rocklatan: Requires trial of any generic formulary ophthalmic glaucoma medication or Lumigan

    Coverage duration: 1 year; document trial

    Rytary: Requires trial of generic oral extended‑release carbidopa & levodopa prior to coverage

    Coverage duration: 1 year; document trial

    Farxiga / Jardiance: Requires trial of generic dapagliflozin prior to coverage; exception: Jardiance when used to reduce risk of cardiovascular death in adults with T2DM and established CVD is not subject to step therapy

    Document trial or exception

    Febuxostat: Requires trial of or documented contraindication to allopurinol before coverage

    Coverage duration: lifetime; document trial or contraindication

    Coverage for Adbry excludes concurrent use with any other biologic or targeted DMARD indicated for the same condition. This is an explicit exclusion and will be a basis for denial if documentation shows overlap with another biologic/targeted DMARD for the same diagnosis. (Coverage details: age ≥12 years; PA required; duration 1 year.)

    Requests for tadalafil will be denied when the member is receiving concomitant nitrate therapy. The policy explicitly states coverage is not provided for tadalafil in situations where patients are on nitrate medications; clinical documentation should confirm absence of nitrates prior to approval.

    Budesonide ER is not covered for the maintenance of remission in ulcerative colitis. The policy lists this as an explicit non‑coverage statement for that specific use.

    The policy repeats that tadalafil is not covered for patients receiving concurrent nitrate therapy. Prior authorization reviewers should confirm medication lists to ensure no concomitant nitrates before approving tadalafil for BPH.

    Dalfampridine ER is excluded from coverage if the patient is wheelchair bound or becomes wheelchair bound. A baseline T25FW must be submitted for initiation and reauthorization requires documentation of stability or improvement on the timed 25‑foot walk; coverage will be denied where wheelchair dependence is documented.

    Many biologic and targeted DMARDs in this policy carry a common restriction: they cannot be used in combination with another biologic or targeted DMARD indicated for the same condition. This combination exclusion is listed across multiple product entries and may trigger denial if concurrent therapy is documented. Providers must show the requested biologic is not being given with another biologic/targeted DMARD for the same diagnosis.

    The policy consistently disallows combination biologic therapy: a product cannot be used in combination with another biologic or targeted DMARD indicated for the same condition. This prohibition appears in multiple product entries (for example, Fasenra and other tumor‑necrosis factor/adalimumab‑class entries) and is an explicit exclusion that may lead to denial if concurrent biologic use is present.

    Certain agents in the formulary are expressly excluded when used solely for treatment of weight loss. The policy states that coverage will be denied if the indication documented is weight loss only; providers must document an approved medical diagnosis (e.g., T2DM with laboratory confirmation) to support coverage.

    Codes, Clinical Thresholds and Key Values

    Products Affected (examples from document)NDC | drug name
    Braftovi CAPS 75MGDrug/product listing as shown
    Listed products (partial)mixed
    Lynparza TABSProduct name as listed
    Mekinist formulationsmixed
    Mekinist TABSMekinist tablet formulation
    Mekinist SOLRMekinist liquid/solution formulation
    inv-111: Eosinophil count
    Eosinophil count threshold>= 150 cells per microliter
    Use caseRequired for eosinophilic asthma (EA) at initiation of treatment
    Related product exampleDupixent EA indication references this threshold
    inv-112: Weight for Ebglyss
    Minimum weight>= 40 kilograms
    Related productEbglyss requires patient weight documentation per initiation criteria
    Age noteApplied in product entry for patients >=12 years (where age listed) — verify per product-specific criteria
    inv-113: Eosinophil count
    Eosinophil count (EA initiation)>= 150 cells per microliter
    IndicationRequired for Fasenra coverage for eosinophilic asthma at treatment initiation
    ReauthorizationReauthorization requires documentation of positive clinical response
    inv-114: Bone mineral density (T-score)
    BMD (T-score) threshold<= -2.5
    Documentation requiredRequires documentation of bone mineral density (T-score at or below -2.5)
    Prerequisite therapyCoverage requires trial of specified bisphosphonate agents (Jubbonti or Stoboclo) and an oral or IV bisphosphonate unless unable to be treated
    inv-115: A1c or glucose thresholds for T2DM
    Diagnostic A1c / glucose thresholdsA1c >= 6.5% OR fasting plasma glucose >= 126 mg/dL OR 2-hour plasma glucose >= 200 mg/dL
    ApplicationUsed to document Type 2 diabetes mellitus for GLP-1/incretin agent coverage (excludes weight-loss-only use)
    Alternate A1c threshold referenceHemoglobin A1c >= 6.5% also listed for diabetes documentation
    inv-116: Hemoglobin A1c
    Hemoglobin A1c requirement>= 6.5%
    ContextUsed as documentation for Type 2 diabetes mellitus when requesting diabetes-related therapies
    Exclusion noteAgents are excluded if used for weight-loss only — confirm diagnosis of T2DM
    inv-117: Eosinophil count thresholds
    EA initiation threshold>= 150 cells/µL at initiation
    COPD threshold>=150 cells/µL current OR >=300 cells/µL within past 12 months
    HES threshold>=1000 cells/µL at initiation
    inv-118: Baseline platelet count
    Baseline platelet count — ITP< 30,000/mcL
    Baseline platelet count — thrombocytopenia with chronic hepatitis C< 75,000/mcL
    Baseline platelet count — severe aplastic anemia< 30,000/mcL
    inv-119: LDL thresholds on high-intensity statin
    LDL threshold with high-intensity statin (ASCVD)LDL >= 55 mg/dL
    LDL threshold without ASCVDLDL > 70 mg/dL
    TimingLDL must be measured while on a high-intensity statin within the last 120 days
    inv-120: Baseline platelet counts
    Baseline platelet count — ITP< 30,000/mcL
    Baseline platelet count — chronic hepatitis C thrombocytopenia< 75,000/mcL
    Baseline platelet count — severe aplastic anemia< 30,000/mcL
    inv-121: Liver fibrosis stage for NASH/MASH
    Liver fibrosis stageStage F2 to F3 verified by FibroScan or other imaging-based non-invasive liver disease assessment
    Prerequisite therapyTrial of semaglutide required prior to coverage for NASH/MASH
    Renewal criteriaRenewal requires no progression to cirrhosis AND either NASH/MASH resolution or >=1-stage fibrosis improvement without worsening NASH/MASH or imaging/blood-based improvement/stabilization
    inv-122: Bone mineral density (T-score)
    BMD (T-score) threshold<= -2.5
    Documentation requirementRequires documentation of bone mineral density showing T-score <= -2.5 for coverage (e.g., Tymlos, Teriparatide)
    Prerequisite therapyCoverage requires trials of specified agents (Jubbonti or Stoboclo and oral or IV bisphosphonate) unless unable to be treated
    inv-123: Tetrabenazine dose CYP2D6 testing threshold
    CYP2D6 testing threshold for tetrabenazine> 50 mg per day
    RequirementDocumentation of patient's CYP2D6 genotype required for doses above 50 mg/day
    Exclusion contextTetrabenazine not covered for patients with hepatic impairment, active suicidal ideation, or concurrent MAOI/reserpine use
    inv-124: Verquvo LVEF threshold
    Verquvo LVEF threshold< 45%
    Clinical contextRequired for coverage in chronic heart failure NYHA class II-IV with additional hospitalization or IV diuretic criteria
    Combination therapyMust be taken in combination with recommended heart failure therapies unless contraindicated
    inv-125: IgE ranges for Xolair
    Xolair IgE ranges — allergic asthma (>=12 yrs)IgE >30 and <700 IU/mL
    Xolair IgE ranges — children 6–12 yrsIgE >30 and <1300 IU/mL
    Xolair IgE ranges — CRSwNPIgE 30–1500 IU/mL
    inv-126: Voydeya lab thresholds for PNH EVH
    Voydeya lab thresholds — hemoglobinHemoglobin <= 9.5 g/dL
    Voydeya lab thresholds — reticulocyte countAbsolute reticulocyte count >= 120 x 10^9/L
    Combination requirementUse only in combination with Soliris or Ultomiris for EVH in PNH

    Prior Authorization, Step Therapy and Documentation Requirements

    Prior Authorization

    PA/ST required for listed drugs

    Prior authorization (PA) or step therapy (ST) is required for many drugs listed in this formulary; clinical and/or administrative criteria must be met before coverage is provided.

    Prior Authorization

    Adbry PA criteria (summary)

    Adbry requires prior authorization for atopic dermatitis in patients ≥12 years with moderate to severe disease and a trial and failure of one listed topical or systemic therapy; reauthorization requires documentation of positive clinical response and dosing for patients <100 kg is limited after 16 weeks unless justified.

    • Age ≥ 12 years; diagnosis of moderate to severe atopic dermatitis
    • Trial and treatment failure of one: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil
    • Reauthorization: documentation of positive clinical response; dosing limit for <100 kg after 16 weeks (300 mg q4w) unless rationale provided
    Prior Authorization

    Prior authorization and duration

    Prior authorization is required for the listed Part D specialty drugs and, unless specified otherwise, coverage durations are commonly set to one year.

    • Coverage duration default: 1 year for many products
    Denial Risk

    Combination biologic/DMARD restriction

    Biologic and targeted DMARD agents cannot be used in combination with another biologic or targeted DMARD indicated for the same condition; such combination use is an exclusion and may trigger denial.

    • Applies across multiple biologic/targeted DMARD product entries
    Prior Authorization

    Prior authorization and coverage duration

    Prior authorization is required for many Part D drugs listed and, unless otherwise specified, approval is generally granted for one year.

    • Some products have different durations where noted (e.g., Praluent: 3 years; select products: lifetime)
    Prior Authorization

    Prior authorization and coverage duration

    Many Part D specialty products require prior authorization with coverage typically granted for one year and may require documented trials of prerequisite Part D drugs where specified.

    • Providers must document required prior trials when indicated to avoid denial
    Prior Authorization

    Lynparza PA requirements

    Lynparza (tablets) requires prior authorization with a one‑year coverage duration and indication-specific prerequisite therapies (for example, prior platinum‑based chemotherapy for BRCA‑mutated ovarian cancer).

    • Document prior platinum‑based chemotherapy where applicable
    Prior Authorization

    Mekinist PA requirements

    Mekinist (tablet and liquid formulations) requires prior authorization with one‑year duration; BRAF V600E/V600K mutated indications are provided as monotherapy only for BRAF‑inhibitor–treatment–naive patients otherwise combination use or prior trials of specified BRAF/MEK regimens are required.

    • Liquid/solution covered only if patient unable to swallow tablets
    • For many BRAF‑mutant indications, combination with dabrafenib or other BRAF/MEK regimens is required
    Prior Authorization

    Mektovi combination and prerequisite therapy

    Mektovi prior authorization requires combination use with encorafenib for specified melanoma indications and prior trial of vemurafenib + cobimetinib for unresectable or metastatic melanoma with BRAF V600E or V600K.

    • Document prior trial of vemurafenib + cobimetinib where required
    Prior Authorization

    Nucala indication-specific PA

    Nucala prior authorization requires indication‑specific diagnostic criteria (e.g., eosinophil thresholds for EA, EGPA features, HES thresholds) and reauthorization requires documentation of positive clinical response.

    • EA: eosinophil criteria and failure to maintain control after appropriate steroid/controller trials
    • HES: eosinophil ≥1000 cells/µL and stability on HES therapy
    • Reauthorization: documentation of clinical response
    Step Therapy

    Nexletol/Nexlizet prerequisite statin trial

    Nexletol and Nexlizet prior authorization require trial of one high‑intensity statin unless statin intolerance or contraindication is documented.

    • Provide documentation of statin trial or intolerance/contraindication
    Prior Authorization

    Opfolda — authorization requirement

    Opfolda coverage for certain indications requires documentation that the patient achieved first complete remission (CR) or CRi after intensive induction chemotherapy and cannot complete intensive curative therapy; authorization duration is one year.

    • For Pompe disease: require serum assay and genetic testing confirming GAA mutation and symptomatic disease
    Step Therapy

    Posaconazole DR — step requirements

    Posaconazole DR prior authorization for IFI prophylaxis or treatment requires trial with two alternative azoles (e.g., fluconazole, itraconazole, voriconazole) before coverage.

    • Prophylaxis: patient at high risk (HSCT with GVHD or prolonged neutropenia) or prior fungal infection
    • Document trials of two alternative azoles
    Prior Authorization

    Praluent — lipid management requirements

    Praluent prior authorization requires documentation of ASCVD/HeFH/primary HLD criteria, LDL measured while on a high‑intensity statin within the last 120 days meeting specified thresholds, and at least 12 weeks of high‑intensity statin unless intolerant; reauthorization requires continued statin and LDL reduction on Praluent.

    • ASCVD: LDL ≥ 55 mg/dL (while on high‑intensity statin)
    • Without ASCVD: LDL > 70 mg/dL (while on high‑intensity statin)
    • Document 12 weeks of high‑intensity statin or intolerance
    Step Therapy

    Bisphosphonate trial required (Jubbonti and Stoboclo mention)

    Coverage for Jubbonti and Stoboclo requires trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate; coverage is also provided if the patient is unable to be treated with both oral and IV bisphosphonates.

    • Document trial or intolerance to oral bisphosphonate (or IV if oral intolerant)
    • Coverage duration noted where specified
    Documentation Required

    Diagnostic and prior therapy requirements for Retevmo

    Retevmo prior authorization requires documentation of RET gene fusion or RET mutation detected by an FDA‑approved test; for some thyroid indications, prior radioactive iodine trial is required when appropriate.

    • Provide FDA‑approved test result for RET fusion/mutation
    • Document prior radioactive iodine trial for thyroid indications when applicable
    Step Therapy

    Step/prior therapy requirements for Rinvoq

    Rinvoq coverage requires prior trials specific to the indication (e.g., trial of a DMARD such as methotrexate for RA; trial of an NSAID for AS/axSpA) and reauthorization requires documentation of positive clinical response and avoidance of combination with potent immunosuppressants or another biologic/targeted DMARD.

    • RA: trial of one DMARD (methotrexate, leflunomide, or sulfasalazine)
    • AS/axSpA: trial of one NSAID
    • Reauthorization: documentation of response and no disallowed combinations
    Prior Authorization

    Prior authorization required

    Prior authorization is required for the listed Part D specialty drugs; coverage durations and prerequisite therapy requirements differ by product and must be documented per product‑specific criteria.

    Prior Authorization

    Tafinlar (liquid) prior auth

    Tafinlar liquid formulation requires prior authorization; coverage for the liquid is limited to patients unable to swallow the capsule and is subject to the same indication‑specific prior therapy requirements as the capsule.

    • Document inability to swallow capsule formulation
    Prior Authorization

    TOCILIZUMAB prior authorization

    Tocilizumab (tocilizumab) requires prior authorization; many indications require trials of specified alternative biologic or targeted DMARD therapies and reauthorization requires documentation of positive clinical response.

    • Cannot be used in combination with another biologic/targeted DMARD for the same condition
    Prior Authorization

    VERZENIO prior authorization

    Verzenio requires prior authorization; coverage for adjuvant or advanced/metastatic breast cancer mandates combination with specific endocrine agents or prior endocrine/chemotherapy per the indication.

    • Document combination partner (tamoxifen or aromatase inhibitor) or prior therapies as specified
    Prior Authorization

    Vanflyta prior authorization

    Vanflyta coverage for newly diagnosed FLT3‑ITD positive AML requires prior authorization and must be used in combination with standard cytarabine and anthracycline induction and cytarabine consolidation.

    • Document combination with standard induction/consolidation regimens
    Prior Authorization

    Prior authorization and coverage duration

    Many listed products require prior authorization with coverage commonly set to one year; providers must follow the product‑specific prerequisite therapy and documentation requirements to obtain approval.

    Step Therapy

    Voquezna — prerequisite therapy

    Voquezna coverage for H. pylori requires documented diagnosis of H. pylori infection and a trial of a guideline‑recommended, generic first‑line regimen (clarithromycin triple therapy or bismuth quadruple therapy) prior to coverage.

    • Document prior trial of clarithromycin triple or bismuth quadruple therapy
    Step Therapy

    Abiraterone 250 mg trial required

    Coverage for several abiraterone products requires prior trial of abiraterone 250 mg tablet strength before coverage of other formulations.

    • Document trial of abiraterone 250 mg tablet
    Step Therapy

    Antidepressant step therapy

    Exxua/Exxua Titration Pack and Trintellix require trial of at least two listed generic antidepressants prior to coverage.

    • Document trials of two listed generics (e.g., bupropion, citalopram, escitalopram, sertraline, etc.)
    Step Therapy

    Aripiprazole trial required

    Abilify Asimtufii and Abilify Maintena require prior trial of oral aripiprazole before approval; coverage duration is lifetime.

    • Document trial of oral aripiprazole
    Prior Authorization

    Products requiring PA

    Products such as Caplyta, Rexulti, Vraylar CAPS, and Zyprexa Relprevv require prior authorization per their product‑specific criteria as listed.

    Prior Authorization

    Aristada PA

    Aristada requires prior authorization with documentation of trial of listed oral or injectable antipsychotics per criteria.

    • Document trials or intolerances as specified in the Aristada entry
    Prior Authorization

    Aristada Initio PA

    Aristada Initio requires prior authorization with trial or documented intolerance to Abilify Maintena or oral aripiprazole.

    • Document trial or intolerance to Abilify Maintena or oral aripiprazole
    Billing Rule

    Supply products PA

    Coverage for specified supply products (gauze, alcohol prep pads) is subject to the criteria in this section; for certain supply products, an insulin claim within the prior 180 days is required.

    • For insulin‑related supplies: document insulin claim within prior 180 days
    Step Therapy

    Pancreatic enzyme PA

    Pancreaze CPEP formulations require prior authorization with documented trial or intolerance to Zenpep before coverage is approved.

    • Document trial of Zenpep or documented intolerance
    Prior Authorization

    Rasuvo prior authorization

    Rasuvo requires prior authorization and a documented trial of generic injectable methotrexate for coverage; coverage duration is lifetime.

    • Document trial of generic injectable methotrexate
    Step Therapy

    Rhopressa prior authorization

    Rhopressa requires trial of any generic formulary ophthalmic glaucoma medication or Lumigan prior to approval; coverage duration is one year.

    • Document trial of generic ophthalmic glaucoma med or Lumigan
    Step Therapy

    Risperidone ER prior authorization

    Risperidone ER requires prior trial of oral risperidone before coverage; coverage duration is lifetime.

    • Document trial of oral risperidone
    Step Therapy

    Rocklatan prior authorization

    Rocklatan requires prior trial of any generic formulary ophthalmic glaucoma medication or Lumigan; coverage duration is one year.

    • Document trial of generic ophthalmic glaucoma med or Lumigan
    Step Therapy

    Rykindo prior authorization

    Rykindo requires prior trial of oral risperidone for coverage; coverage duration is lifetime.

    • Document trial of oral risperidone
    Step Therapy

    Rytary prior authorization

    Rytary requires prior trial of generic oral extended‑release carbidopa & levodopa before approval; coverage duration is one year.

    • Document trial of generic ER carbidopa/levodopa
    Step Therapy

    Farxiga/Jardiance prior authorization

    Farxiga and Jardiance require trial of generic dapagliflozin before approval; exception: step therapy does not apply for Jardiance when used to reduce risk of cardiovascular death in adults with T2DM and established cardiovascular disease.

    • Document trial of generic dapagliflozin unless exception applies
    Step Therapy

    Febuxostat prior authorization

    Febuxostat requires prior trial of allopurinol or documentation of contraindication to allopurinol; coverage duration is lifetime.

    • Document allopurinol trial or contraindication
    Step Therapy

    Prerequisite therapy requirements (general)

    Certain agents require prior trial of specified alternatives or Part D drugs before approval; providers must document trials and failures or contraindications per the product entry.

    Step Therapy

    Anticonvulsant step therapy

    Some anticonvulsant products require documented trial of divalproex or valproic acid and lamotrigine prior to coverage.

    • Document specific anticonvulsant trials as listed
    Step Therapy

    Prior therapy trials required for many products

    Multiple products require documented trials of specified prior therapies (examples: two second‑generation antipsychotics for schizophrenia; trials of generic anticonvulsants for seizure disorders); lack of documentation may trigger denial.

    • Document drug names, durations, and reasons for failure/intolerance
    Step Therapy

    Required trials of prior therapies

    Providers must document prior trials of specified generic alternatives or classes (e.g., two generics for migraine prevention, two generic anticonvulsants for seizures) before coverage is approved.

    Step Therapy

    Step/ prerequisite therapy requirements

    Several products require step or prerequisite therapy trials (e.g., Kevzara and Kineret require trials of two specified agents for RA); document those trials to support the PA request.

    Step Therapy

    Libervant step requirements

    Libervant coverage requires trial of levetiracetam oral solution and documentation that the patient is unable to swallow tablets or capsules.

    • Document trial of levetiracetam oral solution and swallowing inability
    Step Therapy

    Lumakras step/combination requirements

    Lumakras coverage for KRAS G12C‑mutated locally advanced or metastatic NSCLC requires trial of at least one prior systemic therapy; for certain colorectal indications additional combination requirements apply.

    • Document prior systemic therapy trial(s)
    Step Therapy

    Motpoly XR step therapy

    Motpoly XR coverage for seizures requires trial of two generic anticonvulsant alternatives prior to approval.

    • Document trials of two generic anticonvulsants
    Step Therapy

    Ninlaro combination/step requirement

    Ninlaro for multiple myeloma requires at least one prior therapy and use in combination with lenalidomide and dexamethasone.

    • Document prior therapy and combination use
    Step Therapy

    Orenitram — prerequisite agent

    Orenitram coverage requires trial and failure or contraindication to sildenafil prior to approval.

    • Document trial/failure or contraindication to sildenafil
    Step Therapy

    Jubbonti / Stoboclo — bisphosphonate trial

    Jubbonti and Stoboclo require trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate; coverage is also provided if patient unable to be treated with both.

    • Document bisphosphonate trial or intolerance
    Step Therapy

    Step therapy for NASH/MASH

    For NASH/MASH, coverage requires a trial of semaglutide prior to approval and documentation of advanced fibrosis (stage F2–F3) by FibroScan or other imaging‑based non‑invasive assessment.

    • Document semaglutide trial and fibrosis staging
    Step Therapy

    Formulation trial for Secuado

    Secuado coverage for schizophrenia requires trial of asenapine sublingual tablet or documentation of inability to use oral/ODT formulations.

    • Document trial of sublingual asenapine or difficulty with oral/ODT
    Step Therapy

    Step therapy examples

    The formulary includes multiple examples of step therapy requirements—providers must document trials and failures of specified alternatives (e.g., Sunosi requires prior armodafinil trial).

    • Provide records of prior trials and reasons for failure/intolerance
    Step Therapy

    Tymlos step therapy

    Tymlos requires prior trials of JUBBONTI or STOBOCLO and either an oral bisphosphonate (or IV bisphosphonate if intolerant) before approval; document BMD T‑score ≤ −2.5.

    • Document BMD T‑score ≤ −2.5 and bisphosphonate trial or intolerance
    Step Therapy

    Ubrelvy step therapy

    Ubrelvy for acute migraine requires trial of at least two generic triptans (e.g., sumatriptan and rizatriptan) unless contraindicated or not tolerated.

    • Document trials of two triptans or contraindication/intolerance
    Step Therapy

    Xifaxan — step requirements

    Xifaxan 550 mg coverage depends on indication‑specific prior trials: hepatic encephalopathy requires prior trial of lactulose; IBS‑D requires trial of loperamide, dicyclomine, or diphenoxylate/atropine; recurrent C. diff requires trial of vancomycin.

    • Document the specific prior trial relevant to the indication
    Step Therapy

    Winrevair — step requirements

    Winrevair for pulmonary arterial hypertension requires trials of both a generic PDE5 inhibitor (sildenafil or tadalafil) and an ERA (bosentan or ambrisentan) prior to approval.

    • Document trials of both required drug classes
    Step Therapy

    Depression step therapy

    Depression step therapy entries require trial of at least two specified generic antidepressants before coverage of agents like Trintellix/Exxua; failure to document these trials may trigger denial.

    • Provide documentation of two generic antidepressant trials and outcomes
    Step Therapy

    Antidepressant step therapy

    Antidepressant step therapy: coverage of certain antidepressant products requires documented trial of at least two listed generic antidepressants before approval.

    Step Therapy

    Antipsychotic step therapy

    Antipsychotic step therapy: several antipsychotic products require trial of at least one listed conventional antipsychotic agent prior to approval.

    • Document trial of at least one conventional antipsychotic listed
    Step Therapy

    Paliperidone step therapy

    Prior to approval of Invega Hafyera, document trial of paliperidone palmitate once‑monthly for ≥4 months or the three‑month formulation for at least one three‑month cycle.

    • Provide dates and duration of prior paliperidone palmitate formulation trials
    Step Therapy

    SGLT2 inhibitor step therapy

    SGLT2 inhibitor step therapy requires trial of generic dapagliflozin before Farxiga or Jardiance except Jardiance requests for reducing risk of cardiovascular death in adults with T2DM and established CVD are exempt.

    • Document trial of generic dapagliflozin or document qualifying exception
    Documentation Required

    Adbry reauthorization and dosing documentation

    Adbry reauthorization requires documentation of positive clinical response to therapy; dosing restriction applies for patients <100 kg after 16 weeks unless clinical rationale is provided.

    • Submit clinical response documentation at reauthorization
    • Note dosing limitation (300 mg every 4 weeks) for <100 kg responders after 16 weeks unless justified
    Documentation Required

    Bronchitol test documentation

    Bronchitol requires documentation that the member has passed the Bronchitol tolerance test prior to coverage.

    • Submit Bronchitol tolerance test results
    Documentation Required

    Dalfampridine T25FW requirement

    Dalfampridine initiation requires submission of a baseline timed 25‑foot walk (T25FW) test; reauthorization requires documentation of stability or improvement on the T25FW.

    • Provide baseline T25FW and follow‑up results at reauthorization
    Documentation Required

    Weight requirement for Ebglyss

    Ebglyss requires documentation that the patient weighs at least 40 kilograms prior to coverage.

    • Provide weight documentation (≥40 kg)
    Documentation Required

    Dupixent eosinophil requirement

    Dupixent for eosinophilic asthma requires an eosinophil count ≥150 cells/µL at initiation as part of the prior authorization criteria.

    • Document eosinophil count at initiation (≥150 cells/µL)
    Documentation Required

    Required supporting documentation

    Submission of supporting medical records is required for certain products (examples: T2DM labs for GLP‑1 agents, BMD T‑score for teriparatide, prior chemotherapy documentation for Lynparza).

    • Include lab values, imaging, or prior therapy records as specified per product
    Documentation Required

    Reauthorization response documentation

    Reauthorization for many biologic and specialty products generally requires documentation of a positive clinical response to therapy.

    • Provide objective or clinical notes demonstrating improvement
    Documentation Required

    Reauthorization and required documentation

    Reauthorization requests commonly require documentation of continued positive clinical response; some products also require specific diagnostic mutation or prior therapy documentation at renewal.

    • Follow product‑specific reauthorization requirements (e.g., genetic tests, prior therapy evidence)
    Documentation Required

    T2DM documentation

    For liraglutide used to treat type 2 diabetes, submit medical records or labs confirming T2DM diagnosis (A1c ≥6.5% or FPG ≥126 mg/dL or 2‑hr OGTT ≥200 mg/dL).

    • Provide A1c or glucose lab values or chart notes confirming T2DM
    Documentation Required

    Prior chemotherapy documentation

    For Lynparza in certain oncology indications, prior platinum‑based chemotherapy or other specified prior therapies must be documented to support coverage.

    • Include chemotherapy regimen and dates demonstrating prior platinum‑based chemotherapy
    Documentation Required

    Reauthorization documentation (Nucala)

    Nucala reauthorization requires documentation of a positive clinical response to therapy for all indications.

    • Provide clinical outcome evidence at renewal
    Documentation Required

    Diagnostic and clinical documentation (Opfolda)

    Opfolda coverage requires diagnostic confirmation by serum assay showing decreased acid alpha‑glucosidase activity and genetic testing demonstrating a GAA mutation; symptomatic manifestations and lack of improvement on ERT must be documented.

    • Submit serum assay, genetic test results, and clinical symptom documentation
    Documentation Required

    Diagnostic confirmation for Opfolda

    Opfolda diagnostic confirmation requires serum assay showing decreased acid alpha‑glucosidase activity followed by genetic testing showing a GAA mutation.

    Documentation Required

    Laboratory and medication history for Praluent

    Praluent initial approvals require LDL values measured while on a high‑intensity statin within the last 120 days and documentation of statin trials or statin intolerance.

    • Provide LDL value while on high‑intensity statin and evidence of 12 weeks trial or intolerance
    Documentation Required

    Baseline laboratory requirements (Eltrombopag Olamine)

    Eltrombopag Olamine coverage requires baseline platelet counts: ITP <30,000/mcL; thrombocytopenia with chronic hepatitis C <75,000/mcL; severe aplastic anemia <30,000/mcL.

    • Document baseline platelet count meeting the specified threshold
    Documentation Required

    Genetic test requirement (Rivfloza)

    Rivfloza (lumasiran) requires genetic testing confirming AGXT mutation for diagnosis of primary hyperoxaluria type 1; coverage exclusions include history of kidney or liver transplant and combination use with OXLUMO.

    • Submit AGXT genetic test results
    • Do not request coverage for patients with prior kidney or liver transplant
    Documentation Required

    Fibrosis verification (unnamed product)

    For NASH/MASH coverage, verify advanced liver fibrosis (stage F2–F3) by FibroScan or other imaging‑based noninvasive assessment and document a trial of semaglutide prior to approval.

    • Provide fibrosis staging and semaglutide trial documentation
    Documentation Required

    Reauthorization response documentation

    Reauthorization for many biologic indications requires documentation of positive clinical response to therapy; submit objective or clinical notes demonstrating benefit.

    Documentation Required

    CYP2D6 testing for tetrabenazine

    Tetrabenazine documentation: CYP2D6 genotype testing is required for doses above 50 mg/day; coverage is excluded for hepatic impairment, active suicidal ideation, untreated/ inadequately treated depression, or concurrent MAO inhibitor or reserpine use.

    • Provide CYP2D6 genotype when dose >50 mg/day
    • Do not request coverage if exclusion conditions present
    Documentation Required

    BMD requirement for Tymlos

    Tymlos coverage requires documentation of bone mineral density with a T‑score ≤ −2.5 prior to approval.

    • Submit BMD T‑score documentation (≤ −2.5)
    Documentation Required

    Clinical documentation for Verquvo

    Verquvo coverage requires documentation of chronic heart failure NYHA class II–IV with LVEF <45% and evidence of recent hospitalization for heart failure or outpatient IV diuretic use as specified.

    • Provide LVEF and hospitalization or IV diuretic documentation
    Documentation Required

    Diagnosis required (H. pylori)

    Voquezna regimens for H. pylori require a documented diagnosis of H. pylori infection before coverage.

    • Provide test results confirming H. pylori infection
    Documentation Required

    Diagnostic confirmation (Demodex blepharitis)

    Xdemvy for Demodex blepharitis requires confirmation of diagnosis via presence of collarettes on slit‑lamp exam.

    • Submit slit‑lamp exam findings documenting collarettes
    Documentation Required

    Laboratory/diagnostic requirements (Xolair)

    Xolair for allergic asthma requires IgE within specified age‑based ranges and positive skin test or in vitro reactivity to a perennial aeroallergen; reauthorization requires positive clinical response and combination biologic use is excluded.

    • IgE ranges: adults ≥12 yrs: >30 and <700 IU/mL; 6–12 yrs: >30 and <1300 IU/mL; CRSwNP: 30–1500 IU/mL
    • Provide allergen reactivity testing and clinical response documentation
    Documentation Required

    Zilbrysq required documentation

    Zilbrysq coverage for myasthenia gravis requires documentation of anti‑AChR antibody positive MG plus one confirmatory test (edrophonium, clinical response to cholinesterase inhibitors, or electrophysiological evidence) and prior 12‑week courses of listed immunosuppressants unless contraindicated.

    • Submit anti‑AChR antibody result and confirmatory test
    • Document prior immunosuppressant therapy courses or contraindications
    Documentation Required

    Zurzuvae required documentation

    Zurzuvae for postpartum depression coverage requires documentation of onset in the third trimester or within 4 weeks postpartum and that the member is ≤12 months postpartum.

    • Provide timing of symptom onset and postpartum status (≤12 months)
    Billing Rule

    Insulin claim

    A claim for an insulin product within the prior 180 days must be documented for coverage of specified supply/insulin‑related products.

    Documentation Required

    Paliperidone trial documentation

    Documentation of trial duration for paliperidone palmitate is required: once‑monthly formulation ≥4 months or three‑month formulation ≥1 three‑month cycle.

    • Provide dates and duration of prior paliperidone palmitate use
    Documentation Required

    Prior trial or intolerance documentation

    Providers must document prior trials or intolerance to the specified alternative generic agents named for each product to support PA/ST requests.

    • Include drug names, trial duration, and reason for discontinuation (failure or intolerance)
    Documentation Required

    Required documentation of prior trial or contraindication

    Documentation must show trial of the specified alternative medication (e.g., oral risperidone; generic injectable methotrexate; generic ophthalmic glaucoma medication or Lumigan; generic ER carbidopa/levodopa; generic dapagliflozin) or a documented contraindication as stated for each product.

    • Provide records demonstrating trial, failure, or contraindication per product entry

    Requirements to Start Therapy

    Reauthorization and Ongoing Use

    Step Therapy Tables and Prior Trials

    Step therapy requirementDetails
    Prior trial of specified formulary or Part D drugs required where indicatedCriteria specifies that many products require a documented trial of listed alternative Part D agents before coverage is approved (examples: Adbry, multiple oncology and specialty agents).
    Source examplesSee product entries requiring prerequisite Part D drugs; e.g., Adbry requires prerequisite Part D drug use for atopic dermatitis (chunk 2).
    Step therapy requirementDetails
    Specified trials of alternative therapies required before approvalSeveral products mandate trials of named alternative therapies (e.g., two second‑generation antipsychotics for schizophrenia; trial of high‑intensity statin for Nexletol/Nexlizet).
    Source examplesSee schizophrenia (chunk 20), Nexletol/Nexlizet statin requirement (chunk 97).
    Step therapy requirementDetails
    Trials of specified generic alternatives or named therapies requiredFor seizure and migraine products many entries require trials of at least two generic anticonvulsants or two generic migraine preventives prior to coverage.
    Source examplesMotpoly XR and other seizure entries require two generic anticonvulsant trials (chunk 93); migraine preventive requirements listed (chunk 36).
    Step therapy requirementDetails
    Prior trials or prior lines of systemic therapy required for select productsMany oncology and specialty agents require prior lines of therapy or specific prior regimens before approval (examples cited per product).
    Source examplesIclusig requires prior kinase inhibitor trials (chunk 56); Lenvima/Lorbrena/Lumakras combination or prior therapy rules (chunks 71,77).
    Step therapy requirementDetails
    Cancer products: specified systemic chemotherapy or combination therapy prerequisitesMultiple cancer products list required prior systemic chemotherapies or combination partners as prerequisites to coverage.
    Source examplesLenvima metastatic colorectal cancer requirements (chunk 77); Mekinist/Mektovi BRAF combination rules (chunks 86,91).
    Step therapy requirementDetails
    Prior trial of specified medications required before coverageProduct entries commonly state that a trial and failure or intolerance to specified alternatives must be documented prior to approval.
    Source examplesExamples include Ninlaro (prior therapy and combination requirement, chunk 99) and other product entries (multiple chunks).
    Step therapy requirementDetails
    Prior trial of alternative azoles required for Posaconazole DRProphylaxis and treatment coverage requires trial with two of: fluconazole, itraconazole, or voriconazole.
    Source examplesPosaconazole DR prophylaxis/treatment criteria specify trial with two alternative azoles (chunk 120).
    Step therapy requirementDetails
    Prior bisphosphonate therapy required (Jubbonti / Stoboclo)Coverage requires trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate; coverage also provided if unable to be treated with both.
    Source examplesJubbonti and Stoboclo bisphosphonate prerequisite explicitly stated (chunk 126).
    Step therapy requirementDetails
    Prior PAH therapy required for OrenitramOrenitram coverage requires trial and failure or contraindication to sildenafil prior to approval.
    Source examplesOrenitram prerequisite agent requirement noted (chunk 112).
    Step therapy requirementDetails
    Trial of one DMARD required for RA prior to RinvoqRinvoq coverage for RA requires prior trial of a DMARD such as methotrexate, leflunomide, or sulfasalazine.
    Source examplesRinvoq DMARD trial requirement described in product criteria (chunk 136).
    Step therapy requirementDetails
    Trial of one NSAID required for AS / nonradiographic axSpA prior to RinvoqCoverage requires an inadequate response or intolerance to an NSAID before Rinvoq for ankylosing spondylitis and related indications.
    Source examplesRinvoq NSAID prerequisite for AS/axSpA described (chunk 137).
    Step therapy requirementDetails
    Trial of sublingual asenapine or documentation of inability to use oral/ODT required prior to SecuadoSecuado coverage for schizophrenia requires prior trial of asenapine sublingual tablet or documented difficulty with oral/ODT formulations.
    Source examplesSecuado formulation trial requirement shown (chunk 145).
    Step therapy requirementDetails
    Step therapy required prior to coverage (general entries)Multiple product entries denote step therapy is required; product-specific lines list the required alternative(s).
    Source examplesSeveral entries mark 'Criteria DOES require use of a prerequisite Part D drug' across product list (multiple chunks such as 77, 151).
    Step therapy requirementDetails
    Step therapy required prior to coverage (additional entries)Other listed products similarly require documented trials of prior agents before approval; see product-level entries for specifics.
    Source examplesExamples include Spritam (chunk 149), Sunosi (chunk 152) and others indicating prerequisite therapy.
    Step therapy requirementDetails
    Tymlos: prior trials required (Jubbonti/Stoboclo + bisphosphonate)Tymlos coverage requires prior trial of Jubbonti or Stoboclo and either an oral bisphosphonate (or IV bisphosphonate if intolerant) before approval.
    Source examplesTymlos BMD and prerequisite therapy requirements detailed (chunk 174).
    Step therapy requirementDetails
    Ubrelvy acute migraine: two generic triptans required prior to coverageCoverage for acute migraine with Ubrelvy requires trial of at least two generic triptans unless contraindicated or not tolerated.
    Source examplesUbrelvy step therapy described (chunk 175).
    Step therapy requirementDetails
    Step therapy required for select products per product-specific entriesSome products require step therapy with specified generics or regimens depending on indication (e.g., H. pylori, Xifaxan indications, PAH therapies).
    Source examplesVoquezna H. pylori (chunk 181), Xifaxan indication-specific requirements (chunk 193), Voranigo/Winrevair PAH prerequisites (chunks 187, 181).
    Step therapy requirementDetails
    Trial of at least two specified generic antidepressants required before Exxua/TrintellixAntidepressant-class step therapy mandates documented trials of two listed generic antidepressants prior to coverage; coverage duration is lifetime.
    Source examplesAntidepressant trial list and lifetime coverage noted (chunk 216).
    Step therapy requirementDetails
    Trial of oral aripiprazole required before Abilify Asimtufii and Abilify MaintenaCoverage for these aripiprazole formulations requires prior trial of oral aripiprazole; coverage duration is lifetime.
    Source examplesAripiprazole trial requirement specified (chunks 212,214).
    Step therapy requirementDetails
    Trial of at least two listed generic antidepressants required before coverage (general)Multiple antidepressant product entries repeat the requirement for two prior generic antidepressant trials before approval.
    Source examplesAntidepressant step therapy policy repeated (chunk 216).
    Step therapy requirementDetails
    Trial of at least one listed conventional antipsychotic required before coverageProduct groups requiring conventional antipsychotic trial list the acceptable agents; failure/intolerance must be documented.
    Source examplesConventional antipsychotic list and requirement provided (chunk 218).
    Step therapy requirementDetails
    Trial or intolerance to Zenpep required before Pancreaze coveragePancreaze CPEP formulations require documentation of prior trial or intolerance to Zenpep; coverage duration is lifetime.
    Source examplesPancreaze prerequisite documented (chunk 232).
    Step therapy requirementDetails
    Trial of generic dapagliflozin before Farxiga or Jardiance (exception noted)Farxiga and Jardiance generally require prior trial of generic dapagliflozin; exception for Jardiance when used to reduce cardiovascular death risk in T2DM with established CVD.
    Source examplesFarxiga/Jardiance step therapy and exception described (chunk 248).
    Site of careDetails
    hospital outpatient | infusion center | home (dependent on circumstances)Coverage determination may depend on the use and setting of the drug; submit information describing use and setting to determine Part B vs Part D coverage.

    Place of Service Considerations

    Note

    hospital outpatient | infusion center | home (dependent on circumstances)

    Coverage determination may depend on the drug use setting (Part B vs Part D); submit information describing use and setting (hospital outpatient, infusion center, or home) to determine appropriate benefit.

    • Provide site‑of‑care details to clarify Part B vs Part D coverage

    Policy Background and Scope

    This PA/ST program is intended to ensure members receive appropriate, evidence‑based, and cost‑effective drug therapy in line with the payer's Pharmacy & Therapeutics recommendations. It outlines prior authorization and step‑therapy requirements, indication‑specific diagnostic and laboratory thresholds, documentation expectations for initiation and reauthorization, and explicit exclusions that may trigger denials. Providers submitting requests should follow the product‑specific criteria, supply required supporting records (for example, labs, baseline functional tests, prior trial documentation), and confirm no disallowed combinations or contraindicated co‑therapies are present to avoid administrative or clinical denials.

    Key Definitions

    inv-256: Prior authorization (PA)
    DefinitionPrior authorization (PA): clinical and/or administrative criteria that must be met before coverage is provided.
    Typical durationPA approvals in this document commonly specify coverage durations of one year unless otherwise noted
    Action for providersProvider must submit required clinical documentation to demonstrate criteria are met
    inv-257: Step therapy (ST)
    DefinitionStep therapy (ST): requirement to try one or more formulary drugs prior to coverage of the requested drug.
    ApplicationMany products in this formulary require documented trials of specified alternatives before approval
    Exception handlingExceptions may be allowed for intolerance or contraindications where documented
    inv-258: Eosinophilic asthma (EA)
    DefinitionEosinophilic asthma (EA): diagnosis requires eosinophil count >=150 cells per microliter at treatment initiation
    Associated requirementsAlso requires failure to maintain control after systemic corticosteroids or high-dose inhaled corticosteroids plus trial of an additional controller
    Product examplesAppears in Fasenra and Dupixent EA indications
    inv-259: Timed 25-foot walk (T25FW)
    DefinitionTimed 25-foot walk (T25FW): baseline T25FW required prior to initiation of Dalfampridine; reauthorization requires stability or improvement
    DocumentationSubmission of baseline T25FW test is required with PA request
    ExclusionDalfampridine is excluded if patient is wheelchair bound or becomes wheelchair bound
    inv-260: Eosinophilic asthma (EA) initiation eosinophil threshold
    Initiation eosinophil threshold>= 150 cells per microliter at initiation
    ProductsReferenced for Dupixent and Fasenra eosinophilic asthma indications
    ReauthorizationRequires documentation of positive clinical response
    inv-261: Teriparatide BMD requirement
    Teriparatide BMD requirementT-score <= -2.5
    Prerequisite therapyRequires trial of Jubbonti or Stoboclo and either an oral bisphosphonate (or IV if intolerant)
    Coverage durationTypically 2 years for teriparatide/Tymlos entries
    inv-262: APDS coverage requires a diagnosis with associated PI3Kδ mutation and documented variant in PIK3CD or PIK3R1 plus clinical symptoms such as recurrent infections or organ dysfunction.
    Required diagnostic confirmationAPDS coverage requires diagnosis of APDS with associated PI3Kδ mutation and documented variant in PIK3CD or PIK3R1
    Clinical featuresPlus documented symptoms such as nodal/extranodal lymphoproliferation, recurrent oto-sino-pulmonary infections, or organ dysfunction
    Combination restrictionCannot be used in combination with an immunosuppressive medication for APDS indication
    inv-263: BRAF V600E or V600K mutation
    Mutation requirementBRAF V600E or V600K mutation required as detected by an FDA-approved test for certain Mekinist indications
    ApplicationUsed for melanoma, NSCLC, anaplastic thyroid cancer, and selected solid tumors per product entry
    Therapy contextMonotherapy allowed only for BRAF-inhibitor treatment–naive patients in some indications; otherwise combination therapy required
    inv-264: EGPA (Eosinophilic granulomatosis with polyangiitis) features
    EGPA features requirementCoverage for EGPA requires diagnosis plus history/presence of asthma and at least two typical EGPA clinical features (e.g., histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity)
    ReauthorizationReauthorization requires documentation of positive clinical response
    Product exampleFasenra EGPA indication
    inv-265: Complete remission (CR) or complete remission with incomplete blood count recovery (CRi) as used for AML post-induction status
    CR / CRi definition useComplete remission (CR) or CRi used to define AML post-induction status for Opfolda eligibility
    ApplicationRequired that patient achieved first CR or CRi after intensive induction chemotherapy and cannot complete intensive curative therapy
    Coverage durationTypically 1 year for this indication
    inv-266: AASLD/IDSA guidance
    Guidance referencedAASLD/IDSA guidance applied for Hepatitis C treatment decisions (e.g., Vosevi)
    ApplicationCriteria will be applied consistent with current AASLD/IDSA guidance
    ImplicationSubmit documentation consistent with guideline recommendations